RT234 - vardenafil inhalation powder ( DrugBank: Vardenafil )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 86 | 肺動脈性肺高血圧症 | 1 |
86. 肺動脈性肺高血圧症
臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04266197 (ClinicalTrials.gov) | September 25, 2020 | 22/1/2020 | Effects of RT234 on Exercise Parameters Accessed by CPET in Subjects With PAH | A Phase 2, Open-label, Single Dose Study to Evaluated the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI) | Respira Therapeutics, Inc. | Precision For Medicine;Argint International | Recruiting | 18 Years | 80 Years | All | 40 | Phase 2 | United States;Serbia |